Monday, October 5, 2026

Cloud ETFs Sink Up to 22% as March CPI Hits 3.3% and 2026 Rate-Cut Odds Fall to 1-in-3

U.S. CPI re-accelerated from 2.4% to 3.3% in March 2026, driven partly by Iran war energy disruptions, cementing a higher-for-longer Federal Reserve posture. Futures markets now put 2026 rate-cut odds at just 1-in-3, applying severe discount-rate pressure on cloud and AI equities. WCLD is down 22%, CLOD off 14%, and SKYY lower by 10% year-to-date.

LM Salvado

April 28, 2026

Cloud ETFs Sink Up to 22% as March CPI Hits 3.3% and 2026 Rate-Cut Odds Fall to 1-in-3
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Cloud ETFs lost between 10% and 22% year-to-date as U.S. inflation re-accelerated and Federal Reserve rate-cut odds collapsed.1 WCLD is down 22%, CLOD off 14%, and SKYY lower by 10% YTD.1 The selloff reflects a mechanical discount-rate squeeze on high-multiple software and AI equities.

U.S. CPI jumped from 2.4% in February 2026 to 3.3% in March 2026.1 Iran's war disrupted Strait of Hormuz energy flows, amplifying the inflationary shock. That supply disruption pushed energy costs higher and drove headline CPI above expectations, cementing a higher-for-longer Fed posture.

Futures markets now price in a 1-in-3 chance of a 2026 Fed rate cut—down sharply from earlier-year expectations of multiple cuts.1 The Federal Reserve remains frozen, unable to pivot as long as inflation holds above target.

30-year mortgage rates are holding above 6.3%, choking housing activity alongside broader risk appetite.1 Gold has surged as investors seek safety. Treasury yields compressed to 4.23%—a flight-to-safety trade, not a signal of monetary easing.1

The Strait of Hormuz is a critical global oil chokepoint. Any escalation of the Iran conflict adds an energy-inflation tail risk the Fed cannot ignore. That geopolitical uncertainty reduces the probability of a rate pivot in 2026.

The valuation math is punishing cloud and AI names specifically. These companies carry elevated price-to-earnings multiples priced on earnings 5 to 10 years out. Higher discount rates shrink the present value of distant cash flows disproportionately. High-multiple stocks take a far harder hit from rising rates than low-multiple ones.

Enterprise AI spending is still accelerating in 2026, but equity valuations are decoupled from operational momentum. Revenue growth cannot offset the mechanical headwind from elevated discount rates. Investors are repricing risk, not fundamentals.

Until CPI sustains a retreat toward 2%—or Hormuz disruptions ease—the rate regime stays entrenched. Cloud and AI multiples face further compression if cut odds deteriorate below 1-in-3.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score6 source documents6 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· April 25, 2026
    3 Market Trends That Could Shape the Rest of 2026
  2. [2]News articleYahoo Finance· April 25, 2026
    3 Cloud Computing ETFs to Buy as Enterprise AI Spending Accelerates in 2026
  3. [3]News articleYahoo Finance· April 18, 2026
    Gold surges on Hormuz news: Here’s what comes next
  4. [4]News articleYahoo Finance· April 20, 2026
    Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
  5. [5]News articleYahoo Finance· April 24, 2026
    Rate Rumble: Mortgage Moves & Credit Scores
  6. [6]News articleYahoo Finance· April 26, 2026
    Why the Housing Market Is Stalling — Sales Fall 3.6% As Mortgage Rates Climb And Forecasts Get Cut

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com